Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC Presented ByDr Justin F. Gainor, Massachusetts General Hospital, USA TrialPhase 1, ARROW ConferenceASCO 2019 15 July, 2019 19:23
Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement ConferenceWCLC 2018 21 November, 2018 23:51